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 Purpose 
Neonates are particularly challenging to treat. Recently, a novel and patented drug delivery 
device containing a rapidly disintegrating tablet held within a modified nipple shield (NSDS) 
was designed to deliver medication to infants during breastfeeding. In the present study 
an in vivo Slug Mucosal Irritation (SMI) assay, previously validated for prediction of ocular 
and nasal irritation, was used as an alternative to vertebrate models to anticipate the 
potential maternal dermatological tolerability issues to NSDS tablet components. 
Methods 
This first SMI study evaluated excipients used in solid oral dosage forms. Zinc sulphate was 
selected as the model drug, for its ability to reduce infant mortality from diarrhoeal disease. It 
was blended with GRAS excipients commonly used to manufacture rapidly disintegrating 
solid oral dosage forms. Slugs were exposed to blends slurried in human breast milk to 
assess their stinging, itching or burning potential, using objective values such as mucus 
production to categorize irritation potency  
Results 
There was no irritancy detected for any of the excipients tested, however, mild irritancy was 
observed when excipients were combined with zinc sulphate. 
Conclusion 
These promising results provide evidence to support the continued investigation of the 
tested excipients within NSDS rapidly disintegrating tablet formulations. 
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ABBREVIATIONS  
API: Active Pharmaceutical Ingredient  
BAC: Benzalkonium Chloride 
CP: Contact Period 
GRAS: Generally Recognised as Safe 
HIV: Human Immunodeficiency Virus 
HLTV: human T-lymphotropic virus  
HBM: human breast milk 
MP: Mucus Production 
NC: Negative control 
NSDS: Nipple Shield Delivery System 
PC: positive control 
REC: Research ethic committee 
PBS: phosphate buffered saline 
SIB: Stinging, itching or burning 
SMI: Slug Mucosal Irritation  
 
INTRODUCTION 
Identifying the paediatric drug product technology gap 
The development of age appropriate medicines which deliver an active 
pharmaceutical ingredient (API) to children at the required rate and extent is a 
complex process.  Neonates are a particularly challenging sub-population to address 
for formulation scientists due to issues including dysphagia, taste aversion, and the 
need for frequent dose modifications. (1)  
Liquid formulations have been typically the dosage forms of choice for paediatric 
drug administration, but are often not practical in developing countries because of 
high cost, lack of access to refrigeration, contamination issues and limited shelf life. 
(2, 3, 4) They may also be unpalatable and contain undesirable or unsafe 
preservatives and solvents. (5) Solid oral dosage forms for infants are often scaled 
down from adult doses, and there is currently a debate on the limitations of clinical 
work performed to demonstrate suitability of the dose to the infant. (6, 7) Dispersible 
tablets can also be used, but require clean sources of water for reconstitution. They 
also require administration devices for which the volume of reconstituted suspension 
is calculated based upon body weight, body surface area or age, depending on the 
therapeutic index of the drug. However there is currently a WHO recommendation if 
not push for solid oral dosage forms to maximise drug product stability, particularly in 
developing countries. (8)  
A major contributor to this unacceptable statistic is diarrhoeal disease, the second 
leading cause of mortality in this age group, being responsible for 760,000 deaths 
yearly. (9) A significant proportion of the 1.7 billion annual cases of diarrhoeal 
disease reported globally could be prevented through ready access to clean drinking 
water alongside better sanitation and hygiene, both of which also limit the utility of 
medicines designed to be administered post reconstitution in drinking water.   
 
A potential solution to the paediatric drug product technology gap in neonates 
A novel Nipple Shield Delivery System (NSDS) has been proposed as a means to 
address some of these challenges. (10) This thin disposable device (Figure 1) 
adapted from an existing nipple shield breastfeeding aid (11) to contain a fast 
dispersible tablet, is placed over the mother's breast just before infant feeding. When 
the human breast milk (HBM)passes through the device it releases an API to the 
infant via the milk. Based on patient need, a wide-range of APIs could be delivered 
to infants using the NSDS, such as antibiotics, antivirals, antimalarials, vitamins, 
nutrients, and probiotics. The APIs, which are stored in a dry form prior to 
reconstitution in HBM during administration, could therefore have longer shelf lives 
than other dosage forms. 
The NSDS has the potential to compliment dispersible tablet use in environments 
where infants breastfeed exclusively and remove many of the issues which can 
cause contamination of reconstituted drugs delivered to infants in resource-limited 
countries. More than 5.9 million children under 5 years of age died in 2015.  Many of 
these could have been prevented with access to appropriate forms of simple and 
affordable medicines and corresponding hygienic administration methods. (12)  
Zinc supplements, containing zinc sulphate have been shown to reduce the duration 
of diarrhoea episodes by 25% and are also associated with a 30% reduction in stool 
volume (9).  Zinc supplements are available in developing countries but require cup, 
bottle, or spoon delivery of the reconstituted suspension, limiting breastfeeding infant 
acceptability. Zinc sulphate, for which concentrations in HBM have not been 
conclusively shown to be impacted by maternal supplementation (13), constitutes 
therefore a relevant and important API to be delivered directly to neonates in an age 
appropriate manner.  
One safety consideration raised and addressed in this work, is the potential maternal 
tolerability of a modified NSDS. Specifically assessment of dermatological impacts 
due to potential irritancy of a concentrated suspension/slurry of APIs or excipients in 
HBM on the mother’s nipples is required. Presently the SMI assay was identified and 
explored as an in vivo assessment tool for this novel application. It was initially 
developed at the Laboratory of Pharmaceutical Technology at the University of 
Ghent to predict the mucosal irritation potency of pharmaceutical formulations and 
ingredients. (14, 15) The premise of the test is that slugs that are placed on an 
irritating substance will produce mucus. Tissue damage can be induced which 
results in the release of proteins and enzymes from the mucosal surface. Several 
studies have shown that the SMI assay is a useful tool for evaluating the local 
tolerance of pharmaceutical formulations and ingredients. (15, 16, 17, 18, 19, 20, 21, 
22) A classification prediction model that distinguishes between irritation (mucus 
production) and tissue damage (release of proteins and enzymes) has been 
developed. The SMI study is proposed more acceptable and ethical in terms of the 
principles of reduction, refinement and replacement, compared to previous tests 
such as the Draize test (23), an invasive procedure which involves applying relatively 
large volumes (0.5 mL or 0.5 grams of a test substance to the eye or skin of a 
restrained, conscious mammal (usually a rabbit) and recording its effects. It is a 
simple yet efficient way, to asses mucosal tissue irritation without using large 
numbers of vertebrates such as mice, rabbits or non-human primates or using more 
complex reconstructed human epidermis 3D skin models. 
The relevance of the SMI assay to reliably predict nasal irritation, stinging and 
burning sensations has been demonstrated in a clinical trial using several Over the 
Counter (OTC) liquid nasal formulations, isotonic, and hypertonic saline. (24) It has 
also been shown that an increased mucus production with exposure to diluted 
shampoos was related with an increased incidence of stinging and burning 
sensations in the human eye irritation test. (25) The objective values obtained by 
means of the predictive SMI model for the mucus production, stinging, itching, or 
burning potential of the test blends can be estimated according to four categories 
(none, mild, moderate and severe). The limits for degree of discomfort on nasal and 
ocular mucosal surfaces are summarized in Table 1 (24, 25)  
The purpose of the present study was to attempt to predict the stinging, itching or 
burning potential of a range of GRAS powder blends on the human nipple, some of 
which contain the model compound zinc sulphate, used in the treatment of diarrheal 
disease to support the development of a rapidly disintegrating tablet. 
 
MATERIALS AND METHODS 
Methods 
Slugs 
The parental slugs of Arion lusitanicus were collected in local gardens along Ghent 
and Aalter (Belgium) and bred in an acclimatized room at 18 - 20 °C. Test slugs were 
housed in plastic containers and fed with lettuce, cucumber, carrots, and commercial 
dog food. Slugs weighing between 3 and 6 g were isolated from the cultures two 
days before the start of an experiment. The body wall was inspected carefully for 
evidence of macroscopic injuries. Only slugs with clear tubercles and with a foot 
surface that showed no evidence of injuries were used for testing purposes. The 
slugs were placed in a plastic box lined with paper towel moistened with phosphate 
buffered saline (PBS) (0.01 M phosphate buffer, 0.0027 M potassium chloride, and 
0.137 M sodium chloride) (Sigma Aldrich, St. Louis, MO, USA) at pH 7.4 and were 
kept at 18 – 20 °C. Daily, the body wall of the slugs was wetted with 300 µl PBS 
using a micropipette.  
Human breast milk 
Anonymised HBM samples were obtained from approximately 20 healthy donors 
from the Queen Charlotte's and Chelsea Hospital Milk Bank (Imperial College 
Healthcare NHS Trust). The donors had all consented for their milk to be used for 
research as it was not able to be used for donation. They were screened for HIV 1 
and 2, HTLV I and II, hepatitis B and C, and syphilis, and ethical approval for use 
was obtained from the University of Cambridge (Cambridge Human Biology 
Research Ethics Committee (REC), University of Cambridge (REC number 
HBREC.2012.01). Milk from 10 donors was pooled for the experiment, half of which 
was centrifuged at 5411 g (5500 RPM) using a Sigma 3 –16 PK centrifuge (Sigma–
Zentrifugen, Osterode, Germany) for 15 min. A fat layer obtained at the top of the 
flask was then carefully removed using a curved face spatula, and the remaining milk 
was pooled into a single flask. This fat layer, fat-free milk layer and the milk not 
centrifuged were then combined in this study to achieve a standardised fat content of 
4.6 % wt.  Samples were then placed in 50 mL centrifuge tubes and stored at −80 °C 
to be used thawed prior making the slurries.   
Test slurries  
The following materials were sourced for the manufacture of blends A - I: zinc 
sulphate monohydrate (Sigma, Sigma-Aldrich, Dorset, UK); lactose monohydrate 
(direct compression grade, DFE Pharma Goch, Germany); sodium starch glycolate 
(Explotab, Mendell GmbH Volklingen, Germany); sodium croscarmellose (FMC 
Biopolymer, Girvan, UK); microcrystalline cellulose (MCC) (Avicel PH102, FMC 
Biopolymer, UK); magnesium stearate (Sigma-Aldrich, Dorset, UK); crospovidone 
(Polypasdone XL, Ashland, UK) and sodium stearyl fumarate (Alubra PG-100, FMC 
Biopolymer, UK). 
The following 330 mg blends, corresponding to the composition of one NSDS tablet 
containing 20 mg elemental zinc (6% w/w) based on blend A and I, detailed in Table 
2, were prepared by hand filling the individual components in to 6.5 mL glass 
scintillation vials followed by blending in a Turbula mixer at 44 rpm for 5 minutes.  
Blend A was comprised of a mixture of zinc sulphate and lactose (filler or bulking 
agent) in combination with functional excipients at levels commonly used in the 
formulation design of a rapidly disintegrating immediate release solid oral dosage 
form, namely:  microcrystalline cellulose (compression aid), sodium starch glycolate 
(disintegrant), croscarmellose sodium (disintegrant) and magnesium stearate 
(lubricant).  The composition of the blends E, F, G and H were chosen based on 
variations of the lead platform formulation (A) to comprise lactose and each of the 
functional excipients in blend A individually. An alternative disintegrant 
(crospovidone, blend B) and lubricant (sodium stearyl fumarate, blend C) were also 
evaluated.  Blends D and I acted as controls for zinc sulphate, and comprised 
lactose with all of the functional excipients and zinc sulphate respectively.  The 
blends were reconstituted into an homogenous slurry with the aid of vortex mixing 
until visually suspended, using 1 mL HBM.  This volume was chosen to mimic a 
scenario where burst release of the API and excipients occurred, thus yielding 
potentially a worst case concentration for the compounds. The final slurries were 
designed to represent the most concentrated suspension that would be in contact 
with the mother’s nipple assuming near-instant disintegration of the tablet during 
breastfeeding. 
 
Methods 
The SMI assay 
Before a test was considered valid, the following criteria was met: the negative 
control (PBS) generated a total mucus production less than 5.5% of initial body 
weight to be classified as causing no stinging, itching, or burning; the positive control 
(1 w/v% benzalkonium chloride (BAC) (Sigma Aldrich, St. Louis, MO, USA)) in PBS 
generated a total mucus production above 17.5% of initial body weight to be 
classified as causing severe stinging, itching, and burning.  
The stinging, itching, or burning (SIB) potency of the test items and the negative and 
positive controls were evaluated by placing 3 slugs per treatment group 3 times a 
day on 100 µl of test slurry in a Petri dish. After each 15-min contact period (CP) the 
slugs were transferred for 60 min into a fresh Petri dish on paper towel moistened 
with 1 ml PBS to prevent desiccation. After the third CP the slugs were placed in a 
Petri dish on a membrane filter (cellulose acetate 0.45 µm, 90 mm diameter, 
Sartorius AG, Goettingen, Germany) moistened with 2 ml PBS until the next day. 
The overview of the test procedure is illustrated in figure 2. 
The amount of mucus produced during each contact period was measured by 
weighing the Petri dishes with the test item before and after each 15 minute CP. The 
mucus production was expressed as the % of the body weight. The slugs were 
weighed before and after each 15 minute CP and 24 hours after the first CP. The 
total mucus was calculated for each slug and then the mean per treatment group 
was calculated.  
Based on the endpoints of the SMI assay the stinging, itching, or burning potency of 
the test item(s), as defined in Table 1, was estimated using a classification prediction 
model. Mortality was documented for slugs exposed to each of the sample slurries, 
including the controls and HBM 24 hours after the third CP. 
 
RESULTS AND DISCUSSION 
The primary aim of this research was to evaluate the potential of commonly used 
tablet excipients and zinc sulphate used as an antidiarrheal model compound to 
cause irritation of the human nipple through extrapolation of the SMI assay. This 
utilizes the terrestrial slug Arion lusitanicus. The body wall of the slugs is layered and 
has a mucosal surface. The outer single-layered columnar epithelium contains cells 
with cilia and micro-villi.  Mucus secreting cells cover the subepithelial connective 
tissue. This micro-anatomy is similar to that of the lactiferous ducts of the mother’s 
nipple which are lined by a columnar epithelium supported by myoepithelial cells. 
Hence the SMI was hypothesized to be a potential predictive model for nipple 
irritancy during drug administration via the NSDS.  It was assumed that the results of 
this study would represent a worst case assessment for irritation, since ocular/nasal 
surfaces are more sensitive than skin. 
The average amount of mucus produced during each 15 minute CP and total MP is 
presented in Table 3, Figure 3..  
According to the classification prediction model of the SMI test, the negative control 
(PBS) did not induce reactions in the slugs (total MP < 3-5.5%). The positive control 
on the other hand (BAC 1% w/v) induced, as expected, a high mucus production 
during each contact period (total MP ≥ 17.5%) resulting in a classification 
corresponding to severe stinging, itching, and burning (SIB) reactions. The 
acceptance criteria were met and the experiment was considered valid. Graphical 
summaries of the data are presented in Figures 3 and 4. 
The total mucus production values for the reconstituted blends are bracketed by the 
positive and negative controls.  Slugs treated with HBM did not produce an 
increased amount of mucus compared to the negative control. Similarly the blends 
that did not contain zinc sulphate did not increase mucus to production to a level at 
which it could be classified as “mildly irritant” (Table 1), with the exception of blend H 
containing lactose and magnesium stearate, which only just exceeded by 0.1% the 
limit for “no irritation” as classified using the ocular classification only (Table 1 and 
Table 2).  . The total MP for HBM is only slightly negative, and it is therefore 
concluded that HBM was tolerated very well, resulting in a classification as not 
causing discomfort. The negative MP been induced (< -0.7%) may have also 
resulted in tissue damage, but this was not the case. 
Slugs treated with blends B, C, D, E, F, and G produced only a slightly increased 
amount of mucus during each contact period, compared to the negative control.  All 
placebo blends resulted in a total MP <3 and 5.5%, corresponding with the 
classification “no SIB reactions”, suggesting acceptable tolerability. For all placebo 
blends the first contact induced the highest MP, but was much lower during the 
second and third CP.  The slightly negative mucus production that was observed for 
the negative control in the third CP was hypothesised to be due to the fact that the 
slugs produced only a minimal amount of mucus during each contact period and also 
that only a minimal amount of the test substance remains on the body wall of the 
slugs.  
Slugs treated with blends A and I, both containing the API zinc sulphate at a 
concentration of approximately 6% w/w, produced a higher amount of mucus during 
each CP in comparison with the negative control and all other blends tested. For 
blend A, the total MP also increased for the first two CPs; in the third CP it was lower 
than during the first CP. For blend I, MP was comparable during the first and second 
CPs, but increased substantially during the third contact period. This is however 
within the accepted limits. Similar reactions were observed in other experiments, 
where there is a certain tolerance for the the first two CPs, and then an overreaction 
in the third CP. Although it can be interesting to look at the results of the three CPs 
separately, it is the total MP over the three CPs together that is used for the 
classification, as there can be quite some variability in the slugs’ reactions. Both 
blends induced a total MP between 10% and 17.5% and were therefore classified as 
causing moderate SIB reactions.   
With an n of 3 for each of the reconstituted slurries, considered alongside formulation 
(e.g. suspension homogeneity, which was not evaluated) and in vivo variability, it is 
not possible to assign statistical similarities or differences between the formulations 
in terms of mucus production, with a large degree of confidence.  However, the data 
suggests that the zinc sulphate is the major contributing factor to mucosal irritancy, 
and that the lack of response to the GRAS excipients evaluated promotes a large 
formulation design space.  It is to be noted that the concentrations tested represent a 
higher concentration than would be expected to be released using the NSDS, since it 
would likely take more than 1 mL of HBM to disintegrate a tablet during use. (10) 
Therefore, zinc sulfate may not cause as much irritancy as implied by this worst case 
study. 
No mortality was observed immediately following the three CPs, however 24 hours 
after the final CP, two out of three slugs had died in the cohort exposed to the 
positive controls as well as formulations A and I (both containing zinc sulphate).  The 
observed mortality in the slugs exposed to the positive control, was not surprising. 
Slugs treated with benzalkonium chloride using a similar protocol (30 min exposure 
to irritant each day for 5 days), often indicate tissue damage after the first contact 
period. (15, 16) This damage accumulates over time, inducing mortality of the slugs. 
In the current study, damage also occurred after exposure to benzalkonium chloride, 
although this was not quantified using microscopy, resulting in the observed 
mortality. 
Further, zinc salts (including sulphate) have been previously demonstrated to be 
highly toxic to freshwater fish and invertebrates and metal sulphates have been 
incorporated into proprietary slug and snail control products. (26) Exposure to 
elemental zinc in food (albeit at much higher concentrations) has been shown to 
have negative developmental impact on slugs. (27, 28)  
The relationship between API chemical structure and the endpoints mortality and 
MP, has previously been studied for the antimicrobial agent, benzalkonium chloride, 
and it was concluded that the activity and toxicity of different analogues depend on 
the alkyl chain length of the bactericidal molecule. (16) The slug mortality and 
increase in MP of the slugs exposed to slurries containing zinc sulphate appears to 
be due to the API and possibly related to its chemical structure; further investigations 
around API structure / SMI assay activity may help to better validate the model for 
different applications.  While the SMI data generated in this study suggest a 
possibility of local irritation on the human skin, the dermatological impact may be 
less than implied with this relatively non-invasive testing method, when nasal and 
ocular classification scales are used, as these are likely to be more sensitive than 
human skin. 
Further validation of the model is required to build an in vivo / in vivo correlation 
between the SMI model and irritancy of the breastfeeding nipple during 
administration of a rapidly disintegrating immediate release tablet via the NSDS. 
Such a correlation would be a useful pre-formulation tool to assess risk during early 
formulation development.  Additional opportunities to improve the predictiveness of 
the model for the selection of APIs for use with the NSDS include gaining a better 
understanding of similarities and differences of the histology of the breastfeeding 
nipple and the slug mucosa, considering species other than Arion lusitanicus for the 
assay, and essentially, optimising exposure time of the slugs to the concentrated 
slurries to correlate to an average breast feed.  Since the average HBM mass 
delivered per feed is estimated to be 50-80g of milk over a 7 to 10 minute period, the 
study of the tablet components at lower concentrations, correlating to slower release 
from the NSDS could be tested for irritancy potential. (29, 30, 31) 
 
CONCLUSIONS  
This was the first SMI study to be conducted evaluating excipients used in the 
manufacture of solid oral dosage forms, slurried in HBM. The existing SMI model has 
indicated a potential for local dermatological irritation when zinc sulphate at a 
potentially worst case concentration is delivered via the NSDS, with further 
investigation warranted. Mild irritation is suggested by the change in MP, and body 
weight of the slugs exposed to slurries of lactose and functional GRAS excipients 
that are used to induce rapid release of API from solid oral dosage forms. This 
implies these excipients could be used within functional levels as part of a flexible 
formulation design space that could facilitate the incorporation of a wide range of 
non-irritant APIs, with different physicochemical properties, into tablets for use with 
the NSDS. This could potentially broaden the utility of this novel drug delivery 
platform for the clinical treatment of neonates. 
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